Retro Biosciences, a San Francisco-based biotech startup, is making headlines with its ambitious goal to extend the healthy human lifespan by a decade. The company is in the process of raising a $1 billion Series A funding round, with notable backing from OpenAI CEO Sam Altman. This follows a successful seed round where Altman contributed $180 million, setting the stage for significant advancements in longevity research.
Under the leadership of CEO Joe Betts-LaCroix, Retro Biosciences is focused on discovering and developing drugs to combat age-related diseases such as Alzheimer's. The startup plans to initiate trials for these drugs within the decade, marking a pivotal step in their mission to enhance human health and longevity. Betts-LaCroix emphasizes the importance of rapid development in the biotech field, aiming to bring effective solutions to market as swiftly as possible.
Retro Biosciences' innovative approach includes utilizing a model trained with OpenAI technology to convert regular cells into stem cells, potentially unlocking new pathways in medical science. This collaboration signifies a merging of cutting-edge biotechnology and artificial intelligence, promising novel advancements in the fight against age-related ailments.
The startup's efforts are part of a broader trend among billionaire-backed initiatives aimed at extending human life. Notably, Altos Labs launched in 2022 with $3 billion in funding, supported by Amazon founder Jeff Bezos. Unity Biotechnology, another key player in the longevity space, boasts backing from both Bezos and renowned investor Peter Thiel. Retro Biosciences stands out within this competitive field with its unique approach and strategic partnerships.
Leave a Reply